| 1.32 -0.02 (-1.49%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.86 | 1-year : | 2.18 |
| Resists | First : | 1.6 | Second : | 1.86 |
| Pivot price | 1.33 |
|||
| Supports | First : | 1.18 | Second : | 0.93 |
| MAs | MA(5) : | 1.32 |
MA(20) : | 1.28 |
| MA(100) : | 1.1 |
MA(250) : | 1.16 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 40.4 |
D(3) : | 42.1 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 2.08 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KRON ] has closed above bottom band by 46.5%. Bollinger Bands are 11.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.29 - 1.29 | 1.29 - 1.3 |
| Close: | 1.31 - 1.32 | 1.32 - 1.33 |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Fri, 26 Jul 2024
Acadian Asset Management LLC Boosts Holdings in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Wed, 24 Jul 2024
Kronos Bio (NASDAQ:KRON) Shares Up 9.6% - Defense World
Tue, 23 Jul 2024
Kronos Bio Announces First Patient Dosed with KB-0742 in an - GlobeNewswire
Sat, 15 Jun 2024
Norbert Bischofberger Bought 36% More Shares In Kronos Bio - Simply Wall St
Sun, 09 Jun 2024
Here's Why We're Watching Kronos Bio's (NASDAQ:KRON) Cash Burn Situation - Yahoo Finance
Wed, 05 Jun 2024
Kronos Bio: Still Promising But Riskier Following ASCO Update (NASDAQ:KRON) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 26.9 (%) |
| Held by Institutions | 36.2 (%) |
| Shares Short | 720 (K) |
| Shares Short P.Month | 689 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.27 |
| Profit Margin | 0 % |
| Operating Margin | -762.3 % |
| Return on Assets (ttm) | -28.6 % |
| Return on Equity (ttm) | -64.2 % |
| Qtrly Rev. Growth | 106.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.12 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | 0.57 |
| Price to Sales | 10.45 |
| Price to Cash Flow | -0.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|